Evidence
Am J Addict. 2023 Dec 9. doi: 10.1111/ajad.13505. Online ahead of print.
ABSTRACT
BACKGROUND AND OBJECTIVES: In April 2021, the Department of Health and Human Services released new federal practice guidelines and allowed physicians who wish to treat ≤30 patients with opioid use disorder (OUD) to forego the X-waiver training requirement.
METHODS: This observational study compared annual number, dose, and spending of buprenorphine OUD treatments dispensed in the Medicaid population in 2021 versus 2020 using the CMS State Drug Utilization Data (n = 50 states plus D.C.).
RESULTS: Compared to 2020, there was a slight decrease (-3.1%) in the annual number of buprenorphine prescriptions dispensed but an increase in total doses (+3.2%) and payment (10.6%) for buprenorphine prescriptions in 2021.
DISCUSSION AND CONCLUSIONS: Decrease in number of buprenorphine prescriptions in Medicaid population was observed in 2021.
SCIENTIFIC SIGNIFICANCE: Our findings support the hypothesis generation in which the removal of X-waiver training alone is not adequate to increase prescribing and access to OUD treatment buprenorphine.
PMID:38069608 | DOI:10.1111/ajad.13505
Add to Google Keep
Estimated reading time: 3 minute(s)
Latest: Psychiatryai.com #RAISR4D
Cool Evidence: Engaging Young People and Students in Real-World Evidence ☀️
Real-Time Evidence Search [Psychiatry]
AI Research [Andisearch.com]
Did the 2021 federal change in the practice guidelines for the administration of buprenorphine for treating opioid use disorder increase buprenorphine prescription dispensing in Medicaid population?
🌐 90 Days
VR Related Evidence Matrix
- Buprenorphine prescribing and treatment accessibility in response to regulation changes due to the COVID-19 public health emergency
- Buprenorphine Prescribing and Challenges Faced Among National Health Service Corps Clinicians
- Utilization of long-acting injectable monthly depot buprenorphine for opioid use disorder (OUD) in Kentucky, before and after COVID-19 related buprenorphine access policy changes
- Federal Impacts on Buprenorphine Prescribing in Washington State, 2012 to 2022
- Cognitive processing therapy (CPT) versus individual drug counseling (IDC) for PTSD for veterans with opioid use disorder maintained on buprenorphine
- Access to Mental Health and Substance Use Treatment in Comprehensive Primary Care Plus
- Prescribing practices in opioid agonist treatment and changes in compliance to clinical dosing guidelines in British Columbia, Canada
- Prescription opioid dispensing patterns among patients with schizophrenia or bipolar disorder
- Higher First 30-Day Dose of Buprenorphine for Opioid Use Disorder Treatment Is Associated With Decreased Mortality
- A population-based time-series analysis of opioid agonist treatment dispensed during pregnancy
- Medication-based treatment among rural, primary care patients diagnosed with opioid use disorder and alcohol use disorder
- Stepped Care for Patients to Optimize Whole Recovery (SC-POWR): An Effectiveness Trial Evaluating a Stepped Care Model for Individuals With Opioid Use Disorder and Chronic Pain
- Protocol for the development of a consensus practice guideline To address clinical and regulatory barriers to buprenorphine dispensing in community pharmacy
- Protocol for the development of a consensus practice guideline To address clinical and regulatory barriers to buprenorphine dispensing in community pharmacy
- Characterising methamphetamine/amphetamine use among opioid agonist therapy-seeking adults with prescription-type opioid use disorder in Canada
- Characterising methamphetamine/amphetamine use among opioid agonist therapy-seeking adults with prescription-type opioid use disorder in Canada
- Perceptions around medications for opioid use disorder among a diverse sample of U.S. adults
- Multimodal Acute Pain Management in the Parturient with Opioid Use Disorder: A Review
- Withdrawal during outpatient low dose buprenorphine initiation in people who use fentanyl: a retrospective cohort study
- Levels of engagement among office-based opioid treatment (OBOT) patients with concurrent methamphetamine use
- Withdrawal catastrophizing scale: initial psychometric properties and implications for the study of opioid use disorder and hyperkatifeia
- Unintended consequences of methadone regulation for opioid use disorder treatment among hospitalized patients
- Building bridges to outpatient treatment services for post-overdose care via paramedic buprenorphine field initiation
- Building bridges to outpatient treatment services for post-overdose care via paramedic buprenorphine field initiation
- An Australian retrospective observational cohort comparison of the use of long-acting injectable buprenorphine products
- Provider-patient relationships and trauma among pregnant patients with opioid-use disorder
- Association between opioid use disorder and palliative care: a cohort study using linked health administrative data in Ontario, Canada
- Caring for Hospitalized Adults With Opioid Use Disorder in the Era of Fentanyl: A Review
- Emerging Trends in Opioid Use Disorder Management: A 6-Year Analysis of Emergency Department Visits, Buprenorphine Prescriptions, and Naloxone Distribution (2016-2021)
- Impact of COVID-19 pandemic on prescription of psychotropic medications in the Italian paediatric population during 2020
- Buprenorphine Affects the Initiation and Severity of Interleukin Induced Acute Pancreatitis in Mice
- Rapid Initiation of Injection Naltrexone for Opioid Use Disorder: A Stepped-Wedge Cluster Randomized Clinical Trial
- Opioid use and risks in liver transplant candidates and recipients
- Claims data analysis of provider-to-provider tele-mentoring program impact on opioid prescribing in Missouri
- High-Dose Buprenorphine Initiation: A Scoping Review
- Two-year Opioid Prescription Trends in Local Sanitary Agency Naples 3 South, Campania Region, Italy. Descriptive Analyses and AI-based Translational Perspectives
- Prescribing and Acceptance of Medications for Opioid Use Disorder in VA Primary Care: Veteran and Provider Perspectives
- Trend of using cementless total knee arthroplasty: a nationwide analysis from 2015 to 2021
- Target trial emulation for comparative effectiveness research with observational data: Promise and challenges for studying medications for opioid use disorder
- Neuroimaging of opioid effects in humans across conditions of acute administration, chronic pain therapy, and opioid use disorder
- The lived experiences and treatment needs of women with opioid use disorder and posttraumatic stress symptoms: A mixed methods study of women and providers
- Assessing men with opioid use disorder for testosterone deficiency after the development of symptoms
- Outcomes of an Interprofessional Opioid Training Program for Graduate Students in Nursing and Social Work
- Methadone's Resurgence in Bridging the Treatment Gap in the Overdose Crisis: Position Statement of AMERSA, Inc (Association for Multidisciplinary Education, Research, Substance Use, and Addiction)
- Methadone's Resurgence in Bridging the Treatment Gap in the Overdose Crisis: Position Statement of AMERSA, Inc (Association for Multidisciplinary Education, Research, Substance Use, and Addiction)
- Prevalence of Opioid Use Disorder and Opioid Overdose Rates Among People With Mental Illness
- Regional differences in fatal drug overdose deaths among Black and White individuals in the United States, 2012-2021
- Reduced emergency department use among insured individuals receiving extended-release buprenorphine in a health system setting
- Inequities in naloxone administration among fatal overdose decedents by race and ethnicity in Pennsylvania, 2019-21
- Pediatric Primary Care Clinicians' Perspectives on Telemedicine Use, 2020 Versus 2021
- Opioid versus Benzodiazepine-based Sedation for Mechanically Ventilated Patients in the Internal Medicine Ward
- Off-label prescribing of psychotropics in a psychiatric patient population in Australia
- Untreated Psychiatric and Substance Use Disorders Among Caregivers With Children Reported to Child Protective Services
- Who Provides Outpatient Clinical Care for Adults With ADHD? Analysis of Healthcare Claims by Types of Providers Among Private Insurance and Medicaid Enrollees, 2021
- Clinical effectiveness of pharmacist administration of long-acting injectable buprenorphine: Findings from the EPIC-MATOD study
- Characteristics of Opioid Toxicity Deaths Among Adolescents and Young Adults in Ontario Prior To and During the COVID-19 Pandemic
- Prescription Opioid Dose Change Prior to Fatal Opioid-Detected Overdose
- Do Australians use the prescription pathway when using nicotine vaping products to quit smoking?
- The Americans with Disabilities Act and Medication Assisted Treatment in Correctional Settings
- Prevalence of opioid dependence in Scotland 2015-2020: A multi-parameter estimation of prevalence (MPEP) study
- The influence of familial networks and stigma on prison-based medication initiation for individuals with opioid use disorder: Clinicians' perceptions
- Critical incidents in Colorado's opioid treatment programs: A comparison of the COVID-19 pandemic to previous years
- Exemplar Hospital initiation trial to Enhance Treatment Engagement (EXHIT ENTRE): protocol for CTN-0098B a randomized implementation study to support hospitals in caring for patients with opioid use disorder
- Trends in workplace homicides in the U.S., 1994-2021: An end to years of decline
Evidence Blueprint
Did the 2021 federal change in the practice guidelines for the administration of buprenorphine for treating opioid use disorder increase buprenorphine prescription dispensing in Medicaid population?
☊ AI-Driven Related Evidence Nodes
(recent articles with at least 5 words in title)
More Evidence
Did the 2021 federal change in the practice guidelines for the administration of buprenorphine for treating opioid use disorder increase buprenorphine prescription dispensing in Medicaid population?
🌐 365 Days
VR Related Evidence Matrix
- Removal of Medicaid Prior Authorization Requirements and Buprenorphine Treatment for Opioid Use Disorder
- Buprenorphine and Opioid Use Disorder Training: Graduate Nursing Curricula Recommendations
- Change in opioid and buprenorphine prescribers and prescriptions by specialty, 2016-2021
- Buprenorphine prescribing and treatment accessibility in response to regulation changes due to the COVID-19 public health emergency
- Characteristics and Prescribing Patterns of Clinicians Waivered to Prescribe Buprenorphine for Opioid Use Disorder Before and After Release of New Practice Guidelines
- Buprenorphine Prescribing and Challenges Faced Among National Health Service Corps Clinicians
- Utilization of long-acting injectable monthly depot buprenorphine for opioid use disorder (OUD) in Kentucky, before and after COVID-19 related buprenorphine access policy changes
- An analysis of patterns of distribution of buprenorphine in the United States using ARCOS, Medicaid, and Medicare databases
- Urine drug testing among Medicaid enrollees initiating buprenorphine treatment for opioid use disorder within 9 MODRN states
- Pain Management in Patients With Opioid Use Disorder on Extended-release Buprenorphine: A Case Report
- The End of the X-waiver: Excitement, Apprehension, and Opportunity
- ASAM Clinical Considerations: Buprenorphine Treatment of Opioid Use Disorder for Individuals Using High-potency Synthetic Opioids
- Emergency Department Access to Buprenorphine for Opioid Use Disorder
- Racial and Ethnic Inequities in Buprenorphine and Methadone Utilization Among Reproductive-Age Women with Opioid Use Disorder: an Analysis of Multi-state Medicaid Claims in the USA
- Initiation of Extended-release Depot Buprenorphine in a Patient Subject to a Community Treatment Order for Both Antipsychotic and Opioid Agonist Treatments
- Buprenorphine misinformation and willingness to treat patients with opioid use disorder among primary care-aligned health care professionals
- Doing Our Best in a Broken System: The Urgent Need for Expansion of Medication for Opioid Use Disorder Treatments in the United States
- National Trends in Buprenorphine Treatment for Opioid Use Disorder From 2007 to 2018
- Missed Opportunities: Substance Use Hotline Operator Uncertainty of State Buprenorphine Prescribing via Telemedicine
- Exploring the Association of State Policies and the Trajectories of Buprenorphine Prescriber Patient Caseloads
- Federal Impacts on Buprenorphine Prescribing in Washington State, 2012 to 2022
- The association of medical providers' attitudes about naloxone and people with opioid use disorder and their self-reported "low-barrier" treatment practices
- Changes in Opioid Agonist Treatment Practice in Germany during the COVID-19 Pandemic: What Have Physicians Done, and What Would They Like to Keep Doing?
- Treatment of poppy seed tea misuse with buprenorphine in a telehealth practice: a case series
- Prescriptions for Buprenorphine in Michigan Following an Education Intervention
- Cognitive processing therapy (CPT) versus individual drug counseling (IDC) for PTSD for veterans with opioid use disorder maintained on buprenorphine
- Extended-release Buprenorphine Administered at Discharge in Hospitalized Persons With Opioid Use Disorder: A Case Series
- Patient opinion and acceptance of emergency department buprenorphine/naloxone to-go home initiation packs
- Buprenorphine deregulation as an opioid crisis policy response - A comparative analysis between France and the United States
- Evidence on Buprenorphine Dose Limits: A Review
- Cardiac and mortality outcome differences between methadone, buprenorphine and naltrexone prescriptions in patients with an opioid use disorder
- Pharmacokinetic-pharmacodynamic analysis of drug liking blockade by buprenorphine subcutaneous depot (CAM2038) in participants with opioid use disorder
- An Appraisal of Using Opioids in Patients with Opioid Use Disorder
- Associations of methadone and buprenorphine-naloxone doses with unregulated opioid use, treatment retention, and adverse events in prescription-type opioid use disorders: Exploratory analyses of the OPTIMA study
- Measuring time in buprenorphine treatment stages among people with HIV and opioid use disorder by retention definition and its association with cocaine and hazardous alcohol use
- Opioid use disorder treatment and the role of New Jersey Medicaid policy changes: perspectives of office-based buprenorphine providers
- Buprenorphine adherence and illicit opioid use among patients in treatment for opioid use disorder
- Kratom use disorder: case reports on successful treatment with home induction of buprenorphine-naloxone
- Access to Mental Health and Substance Use Treatment in Comprehensive Primary Care Plus
- Prescribing practices in opioid agonist treatment and changes in compliance to clinical dosing guidelines in British Columbia, Canada
- Acute Pain Management for Patients Maintained on Sublingual Buprenorphine as Medication for Opioid Use Disorder
- Characterizing Acute and Postsurgical Pain Management in Patients Receiving Buprenorphine or Buprenorphine/naloxone
- Trends in Incident Prescriptions for Behavioral Health Medications in the US, 2018-2022
- Expanding access to Medication for Opioid Use Disorder (MOUD) in jails: A comprehensive program evaluation
- Examining the benefit of a higher maintenance dose of extended-release buprenorphine in opioid-injecting participants treated for opioid use disorder
- Association of MOUD ECHO Participation on Expansion of Buprenorphine Prescribing in Rural Primary Care
- Prescription opioid dispensing patterns among patients with schizophrenia or bipolar disorder
- Medical and genetic correlates of long-term buprenorphine treatment in the electronic health records
- The Perceived Role of Withdrawal in Maintaining Opioid Addiction among Adults with Untreated Opioid Use Disorder: A Survey of Syringe Exchange Program Participants
- Survey of barriers and opportunities for prescribing buprenorphine for opioid use disorder in Alabama
- Hospital-based opioid treatment: Expanding and sustaining the model in Texas
- Gabapentin Use Among Individuals Initiating Buprenorphine Treatment for Opioid Use Disorder
- Buprenorphine: two adolescent case reports of bridging the transmucosal form to the extended-release subcutaneous injectable form
- Unfilled prescriptions: Surveying patients' experiences with buprenorphine treatment in Massachusetts before and during the COVID-19 pandemic
- Higher First 30-Day Dose of Buprenorphine for Opioid Use Disorder Treatment Is Associated With Decreased Mortality
- Non-overdose acute care hospitalizations for opioid use disorder among commercially-insured adults: a retrospective cohort study
- Impact of the Communities That HEAL Intervention on Buprenorphine-Waivered Practitioners and Buprenorphine Prescribing: A Prespecified Secondary Analysis of the HCS Randomized Clinical Trial
- Health care use and cost of treatment for adolescents and young adults with opioid use disorder
- Risks of opioid overdose among New York State Medicaid recipients with chronic pain before and during the COVID-19 pandemic
- Differences in medicaid expansion effects on buprenorphine treatment utilization by county rurality and income: A pharmacy data claims analysis from 2009-2018
- A population-based time-series analysis of opioid agonist treatment dispensed during pregnancy
- The impact of the implementation of medication for opioid use disorder and COVID-19 in a statewide correctional system on treatment engagement, postrelease continuation of care, and overdose
- Low-dose Induction of Buprenorphine in Pregnancy: A Case Series
- Low Dose Buprenorphine Initiation: A Guide for the Inpatient Clinician